# Dopamine D3 Receptor Occupancy in Bipolar Depression

> **NCT05060549** · PHASE4 · WITHDRAWN · sponsor: **New York State Psychiatric Institute**

## Conditions studied

- Bipolar Depression

## Interventions

- **DRUG:** Cariprazine

## Key facts

- **NCT ID:** NCT05060549
- **Lead sponsor:** New York State Psychiatric Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2026-01-06
- **Primary completion:** 2027-05-01
- **Final completion:** 2027-05-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding decision
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05060549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05060549, "Dopamine D3 Receptor Occupancy in Bipolar Depression". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05060549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*